DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Asston Pharmaceuticals Ltd (APL) share price today?

Asston Pharmaceuticals Ltd (APL) is trading at ₹63.14 on the BSE, down 3.60% on the day. Source: DocStoX.

What is the PE ratio of Asston Pharmaceuticals Ltd?

Asston Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 10.3 in the Healthcare sector.

What is the market capitalisation of Asston Pharmaceuticals Ltd?

Asston Pharmaceuticals Ltd has a market capitalisation of approximately ₹56 crore.

Asston Pharmaceuticals Ltd

APL·BSE·Healthcare

₹63.14▼ -2.36 (-3.60%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹60.00

₹64.38

52W₹61

₹1263%

Open

₹62.10

High

₹64.38

Low

₹60.00

Prev Close

₹65.50

Volume

72.0K

VWAP

₹61.71

Snapshot

Key fundamentals

Market Cap

₹56 Cr

P/E Ratio

10.28Cheap

P/B Ratio

1.43

EPS

₹6.14

Book Value

₹45.65

ROE

15.50%Strong

ROCE

36.62%Efficient

Dividend Yield

0.00%

Debt / Equity

0.13Low

Face Value

₹10.00

52W High

₹125.50

52W Low

₹61.02

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Strong Buy

Narrow moatHigh uncertainty

Fair value estimate

₹110

▲ 74.6%upside

Trading at ₹63 — 75% below our estimate

BearFair valueBull

₹68₹110₹127

/100

Business quality — Solid

Growth 50Profitability 63Efficiency 100Valuation 96

Plain English

Our view

A steady, established business
Low debt relative to equity

Strengths

Low debt relative to equity
Capital is working hard (ROCE 37%)
Reasonably priced at 10× earnings
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

35% ROE fading to 12% over ~10 yrs, on ₹46 book

₹122

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹68

Analyst target

No analyst coverage

—

Blended fair value₹110

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 37%)
Reasonably priced at 10× earnings
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

10.3Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

15.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

36.6%Efficient

Above 18% means capital is working hard

Debt/Eq

0.13Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹56 Cr

P/B

1.43

EPS

₹6.14

Div Yield

—

What changed

Recent changes

Foreign investors-4.1% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 10.3×

Growth

Strong

+57% rev CAGR

Profitability

Healthy

15.5% ROE

Financial health

Rock solid

D/E 0.13

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹44.43L Cr

Trades50

VWAP₹61.71

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+57.3%

—

10Y

—

Profit

+55.3%

—

10Y

—

EPS

-33.0%

—

10Y

—

Profile

Pros

Company has reduced debt.
Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Earnings include an other income of Rs.6.12 Cr.
Company has high debtors of 524 days.
Working capital days have increased from 259 days to 434 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 4.13 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

51%

Promoter

Promoters

50.7%0.00

Public

40.5%+3.47

FII / FPI

1.9%-4.13

DII

0.0%0.00

Others

6.9%

Total shareholders

687-64 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter50.66%

FII1.91%

Public40.53%

Others6.90%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]